Trial Profile
An Exploratory, Open-label Study to Assess the Effect of P-188 NF (Carmeseal-MD) on Safety, on Respiratory and Cardiac Dysfunction and on Upper Limb Strength in Non-ambulatory Patients With Duchenne Muscular Dystrophy (DMD)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 13 Jan 2023
Price :
$35
*
At a glance
- Drugs Poloxamer 188 (Primary)
- Indications Duchenne muscular dystrophy
- Focus Therapeutic Use
- Sponsors Phrixus Pharmaceuticals
- 09 Jan 2023 Status changed from suspended to discontinued.
- 27 Aug 2019 Planned End Date changed from 1 Nov 2019 to 1 Nov 2020.
- 27 Aug 2019 Planned primary completion date changed from 1 Sep 2019 to 1 Sep 2020.